Free AIM Immunoassay with SRCR2-Selective Antibodies

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods struggle to accurately measure the amount of free AIM in biological samples due to the interference from complex AIM, necessitating a technique to selectively detect free AIM without complex AIM.

Innovation Solution

Development of an anti-AIM monoclonal antibody that specifically reacts with free AIM by recognizing the SRCR2 domain, allowing for the development of immunoassay methods and kits with high specificity and sensitivity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional immunoassay methods are used to detect AIM, then both free AIM and complex AIM are detected, but the measurement precision for free AIM is poor

Engineering Contradiction:
Improvefree AIM measurement precisionVSAvoidability to distinguish free AIM from complex AIM
Core Design Contradiction:
Measurement precisionVSAdaptability or versatility

Solution Approach 1:

The invention segments the detection target into two distinct forms: free AIM and complex AIM. By developing monoclonal antibodies with different specificities (one recognizing only free AIM, another recognizing both free and complex AIM), the assay can differentiate and selectively measure free AIM in the presence of complex AIM, thereby improving measurement precision

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention changes the binding parameter of the antibody by selecting monoclonal antibodies with different epitope specificities. The first monoclonal antibody is selected to bind specifically to free AIM, while the second binds to both free and complex AIM. This parameter change in antibody specificity enables the differentiation and accurate measurement of free AIM

Inventive Principle:
Principle #35Parameter changes

2Measurement precision

If methods are developed to selectively detect free AIM, then measurement precision improves, but device complexity increases

Engineering Contradiction:
Improvefree AIM detection accuracyVSAvoidassay method complexity
Core Design Contradiction:
Measurement precisionVSDevice complexity

Solution Approach 1:

The invention extracts the specific binding capability from the antibody pool by selecting monoclonal antibodies with defined specificities. The first monoclonal antibody is extracted to recognize only free AIM, while the second is extracted to recognize both forms. This extraction of specific binding properties simplifies the assay design compared to using polyclonal antibodies or complex separation methods

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The second monoclonal antibody serves multiple functions: it can detect both free AIM and complex AIM, and when used in combination with the first monoclonal antibody, it enables selective measurement of free AIM through competitive binding or signal differentiation. This multi-functionality reduces the need for additional reagents or complex equipment

Inventive Principle:
Principle #6Universality (Multi-functionality)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables accurate detection of free AIM in biological samples containing both free and complex AIM, enhancing diagnostic precision.

Implementation Method 1

an anti-AIM monoclonal antibody having a property of reacting with free AIM and not reacting with complex AIM

Methodology Applied
Scientific EffectAntigen-antibody reaction:

Data Source

PatentEP3919509B1Method for immunological analysis of free aim in biological sample
Publication Date: 2025.10.08 SEKISUI MEDICAL CO LTD
  • EP3919509B1 patent drawingFigure 1A
  • EP3919509B1 patent drawingFigure 1B
  • EP3919509B1 patent drawingFigure 1C

AI summary

A problem to be solved is to detect only free AIM in a biological sample containing complex AIM and free AIM. The problem can be solved by an immunoassay method for free AIM in a biological sample using an anti-AIM monoclonal antibody having a property of reacting with free AIM and not reacting with complex AIM, wherein the anti-AIM monoclonal antibody is an antibody binding to an epitope in the SRCR2 domain of human AIM.